Neumora Therapeutics Reports Q3 GAAP EPS of -$0.18, Exceeding Estimates

Neumora Therapeutics (NMRA) reported third-quarter earnings with a GAAP earnings per share (EPS) of -$0.18, slightly outperforming market expectations by $0.02. The results provide a narrow beat on the bottom line for the biotechnology company. As of September 30, 2026, Neumora reported having $85.7 million in cash and cash equivalents on its balance sheet. Despite the earnings beat, the company has opted not to provide updated guidance regarding its financial runway at this time.

3 articles from 1 source · updated

Coverage